These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18090674)

  • 1. Is kidney injury a reversible process?
    Chatziantoniou C; Dussaule JC
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):76-81. PubMed ID: 18090674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?
    Chatziantoniou C; Dussaule JC
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F227-34. PubMed ID: 16006588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of renal disease: is it enough to inhibit the action of angiotensin II?
    Dussaule JC; Chatziantoniou C
    Cell Death Differ; 2007 Jul; 14(7):1343-9. PubMed ID: 17396129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reversal of renal fibrosis: lessons from experimental models].
    Dussaule JC; Chatziantoniou C
    Bull Acad Natl Med; 2008 May; 192(5):987-1000; discussion 1000-1. PubMed ID: 19238788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets for prevention and regression of progressive fibrosing renal diseases.
    Eitner F; Floege J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):255-61. PubMed ID: 15816501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and progression of kidney disease.
    Cortinovis M; Perico N; Cattaneo D; Remuzzi G
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aggravating mechanisms of aldosterone on kidney fibrosis.
    Remuzzi G; Cattaneo D; Perico N
    J Am Soc Nephrol; 2008 Aug; 19(8):1459-62. PubMed ID: 18550649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation.
    Savelieva I; Camm J
    Nat Clin Pract Cardiovasc Med; 2008 Jan; 5(1):30-41. PubMed ID: 18094671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin: an endogenous renoprotective factor?
    Hewitson TD; Samuel CS
    Ann N Y Acad Sci; 2009 Apr; 1160():289-93. PubMed ID: 19416206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy.
    Bani-Hani AH; Campbell MT; Meldrum DR; Meldrum KK
    J Urol; 2008 Aug; 180(2):461-8. PubMed ID: 18550128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
    Young MJ
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent perspectives in the mechanisms and therapy of renal sclerosis.
    Menè P
    J Nephrol; 2006; 19(4):413-8. PubMed ID: 17048198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
    Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
    Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal targeting of kinase inhibitors.
    Dolman ME; Fretz MM; Segers GJ; Lacombe M; Prakash J; Storm G; Hennink WE; Kok RJ
    Int J Pharm; 2008 Dec; 364(2):249-57. PubMed ID: 18550305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin pleiotropy against renal injury.
    Kostapanos MS; Liberopoulos EN; Elisaf MS
    J Cardiometab Syndr; 2009; 4(1):E4-9. PubMed ID: 19245508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.
    Perico N; Benigni A; Remuzzi G
    Nat Rev Drug Discov; 2008 Nov; 7(11):936-53. PubMed ID: 18846102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal-epithelial cycling in kidney repair.
    Ishibe S; Cantley LG
    Curr Opin Nephrol Hypertens; 2008 Jul; 17(4):379-85. PubMed ID: 18660674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D; Tanabe A; Naruse M; Morikawa S; Ezaki T; Takano K
    Hypertens Res; 2009 Sep; 32(9):807-15. PubMed ID: 19662019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.